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MaturationAdipose-derived regenerative and stem cells, deﬁned collectively as the stromal vascular fraction (SVF), support
the formation of neovascular networks at the site of implantation. The effect of advancing age on SVF cell popu-
lation effectiveness towards stimulated neovascularization was evaluated.
Methods: SVF was enzymatically isolated from adipose of young (ySVF, 4 months) or old (oSVF, 24 months)
Fisher-344 rats, combinedwith type I collagen and polymerized. Encapsulated SVFwas implanted subcutaneous-
ly into young Rag1 mice for two or four weeks. Angiogenic function of age-dependent SVF was also extensively
evaluated in vitro using standard assays.
Results: In vitro studies indicated no difference in angiogenic function between ySVF and oSVF (viability, prolif-
eration, migration, and tube-formation). At two weeks post-implantation, there was no age-related difference
in percent apoptosis in explanted constructs. By four weeks post-implantation, oSVF implants displayed 36%
less total vessels/mm2, 43% less perfused vessels/mm2, and exhibited greater percent apoptosis compared to
ySVF (n ≥ 12). Blocking thrombospondin-1 (Thbs-1), a protein found to be highly expressed in oSVF but not
ySVF, increased the percent of perfused vascular volume and vessel diameters in oSVF constructs after two
weeks compared to oSVF implants treated with control antibody.
Conclusions: Advancing donor age reduces the potential of adipose-derived SVF to derive a mature microcircula-
tion, but does not hinder initial angiogenesis. However, modulation of Thbs-1 may improve this outcome. This
data suggests that greater pruning, dysfunctional structural adaptation and/or poor maturation with initiation
of blood ﬂow may occur in oSVF.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Peripheral vascular disease (PVD) and myocardial ischemia persist
in part due to the body's inability to spontaneously revascularize
through the processes of angiogenesis and vasculogenesis. Therapeutic
attempts to treat ischemia with angiogenic factors have been largely in-
effective (Collinson and Donnelly, 2004). Cell-based therapies have
been initiated with the hypothesis that cells may provide a more effec-
tivemixture of secreted factors to stimulate revascularization. Previous-
ly our laboratory and others have demonstrated that freshly isolated
adipose-derived regenerative and stem cells can induce new vascular
network formation through the reassembly of endothelial cells at
the site of implantation (Koh et al., 2011; Nunes et al., 2013). The
formation of new patent vessels has been shown to involve both de-
novo vessel formation from existing vessels (angiogenesis) and the for-
mation of new vessels through self-assembly of transplanted cellsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
19A.L. Aird et al. / Experimental Gerontology 63 (2015) 18–26(vasculogenesis). Implanted adipose-derived cells progress through
distinct phases of neovascularization to eventually form a complete vas-
cular network: vasculogenesis/angiogenesis, vascular remodeling and
pruning, and ﬁnally, vascular maturation (LeBlanc et al., 2012; Nunes
et al., 2010).
The majority of studies on neovascularization potential of cells of
mesenchymal origin have used bone marrow-derived sources
(BMSCs). More recently, adipose-derived stromal cells (ADSCs) have
been shown to possess similar pro-angiogenic capabilities. ADSCs
can form vascular networks by direct interactions with endothelial
cells through cell incorporation (Merfeld-Clauss et al., 2010), but
also through extensive paracrine mechanisms to modulate the
process of angiogenesis (Rehman et al., 2004; Yang et al., 2013).
Comparatively, human ADSCs have been shown to exhibit superior
therapeutic potential when compared to human BMSCs in a mouse
hindlimb ischemia model (Kim et al., 2007). Even though clinical
presentations of ischemia so often occur in states of advanced age,
there have been surprisingly few studies utilizing adipose-derived
cells from older individuals to determine age-related potential for vas-
cular therapy. The neovascularization potential of the adipose-derived
regenerative and stem cell population from aged donors may be
diminished.
Advanced age has been reported to be associated with poor wound
healing responses suggesting that an age-related defect exists in the
cell-dependent mechanisms that regulate neovascularization. Whether
the age of the donor renders these cells ineffective in overall neovascu-
larization potential or a deﬁcit in one of the phase components remains
unknown, but is important to ascertain if an autologous cell-based ap-
proach is to be utilized for patients with vascular ischemia. Numerous
studies have suggested that adipose tissue from older humans and ani-
mals demonstrates cellular deﬁciencies, such as lower proliferation
rates and greater susceptibility to apoptosis (Schipper et al., 2008).
The general consensus is mesenchymal stem cells (MSCs) and progeni-
tor cells lose proliferative and differentiation capacity with advancing
age (Stolzing et al., 2008), but this loss of cell function hasn't been inves-
tigated in the heterogeneous adipose-derived stromal vascular fraction
(SVF) cell populations.
The SVF represents a heterogeneous cell population that resides
within adipose tissue and is comprised of endothelial cells, smooth
muscle cells, macrophages, blood cells and mesenchymal stem cells
(Zimmerlin et al., 2010). Adipose-derived cells have recently become
the focus of numerous efforts designed to mitigate ischemia and heart
failure in animal models (Mazo et al., 2008; Miyahara et al., 2006;
Wang et al., 2009; Zhang et al., 2007) and clinical applications (Gir
et al., 2012). Adipose tissue represents an attractive cell source for re-
generative medicine due to the ease of isolation, abundance, and the
ability of some cells to differentiate into various mesodermal cell line-
ages (Lin et al., 2008). The purpose of this study was to directly assess
the age-related neovascularization potential of isolated SVF cells in an
in vivomodel with further in vitro characterization. Our overall hypoth-
esis was that SVF isolated from aged rats (oSVF) would display de-
creased vasculogenic function in vivo compared to cells from young
rats (ySVF), and that this would be decreased due to impaired
capillary-like tube formation. Contrary to our hypothesis, we provide
evidence here that the vasculogenic potential of SVF appears to be
maintained with advancing age, but network maturation is impaired
in oSVF in vivo. We believe greater pruning and/or poor adaptation to
the initiation of perfusion and inosculation results in fewer cells and
vessels maintained when oSVF cells are used.
2. Materials and methods
All animal surgeries were performed in accordance with protocols
approved by the University of Louisville Institutional Animal Care and
Use Committee and the NIH Guide for the Care and Use of Laboratory An-
imals (9th ed., 2011).2.1. SVF Isolation
Young (4 months) and old (24 months) male and female Fischer-
344 rats (Harlan Laboratories, Indianapolis, IN, USA and National Insti-
tute on Aging, Bethesda, MA, USA, respectively) were anesthetized
(40–80mg/kg ketamine and 5–10mg/kg xylazine), epididymal or ovar-
ian fat was excised, and the rat was euthanized by removal of the heart.
The fat was washed in 0.1% bovine serum albumin in phosphate-
buffered saline (BSA–PBS), ﬁnely minced, and enzymatically digested
with 2 mg/mL type I collagenase (type I collagenase, Worthington Bio-
chemical Company, NJ) for 40 min at 37 °C. After digestion, the tissue-
collagenase mixture was centrifuged, buoyant adipocytes were re-
moved, and the top two layers of the cell pellet were retrieved to obtain
the SVF.
2.2. Construct formation and implant
As previously described, young rat SVF (ySVF) or old rat SVF
(oSVF) cells were used immediately after isolation for construct im-
plants by combining with BD Biosciences rat-tail type I collagen
(3.0 × 106 cells/mL) and 4× DMEM to form three-dimensional (3D)
constructs (Nunes et al., 2011). Brieﬂy, two constructs per mouse
were subcutaneously implanted into the dorsal ﬂank of 6 week old im-
munodeﬁcient Rag1 mice (B6;129S7-Rag1tm1Mom/J, Jackson Laborato-
ries, Bar Harbor, MA, USA). At four weeks post-implant, the mice were
perfused with 250 μL of 2 mg/mL dextran–rhodamine (Dex+,
2,000,000 MW, Invitrogen) for 15 min before construct explant to
delineate perfused vessels. One construct from each mouse was desig-
nated for confocal microscopy imaging and the other for immunohisto-
chemistry (IHC). Following explant, IHC constructs were ﬁxed in
paraformaldehydewhile those for confocal imaging were ﬁxed, perme-
abilized, and stained with 0.1 mg/mL ﬂuorescein-conjugated Griffonia
simplicifolia I (GS-1) lectin overnight (Vector Labs) to label all vascular
elements, and confocal laser microscopy was performed (Olympus
model BX61WI; Olympus America Inc, Central Valley, PA).
2.3. Vessel perfusion and vessel density analysis
To estimate the vascular volume index fraction (VVIF), individual
slices of confocal image stacks obtained at 20× magniﬁcation were
processed as previously reported (Nunes et al., 2010). The percent per-
fusion of vasculature is calculated by dividing the volume of perfused
vessels by the entire vessel volume (Dex+VVIF / GS-1+VVIF), averaged
from three image stacks throughout each construct. The absolute num-
ber of Dex+ and GS-1+ vessels was calculated manually by using the
counting tool in Adobe® Photoshop (Adobe Systems Incorporated, San
Jose, CA). Results are presented in multiple aspects: as the number of
GS-1+andDex+vessels permm2, percent perfused vessel volume rel-
ative to total, and vessel diameter distribution for ySVF or oSVF con-
structs. Vessel diameter distribution was calculated by measuring
diameters of all vessels present in a 3D construct (ySVF or oSVF) and
binning them in 5 μm increments.
2.4. LIVE/DEAD assay
The LIVE/DEAD Viability/Cytotoxicity Kit (Life Technologies) was
used per manufacturer's instructions to determine viability after cell
isolation. 3 images/sample were taken with a ﬂuorescent microscope
(Olympus model IX51; Olympus America Inc, Central Valley, PA) and
averaged to determine percent viability ([# live cells / # dead
cells] ∗ 100).
2.5. RNA and RT-qPCR for angiogenic markers
TheRT2 Proﬁler PCRArray for Rat Growth Factors (Qiagen)was used
to evaluate 84 genes related to angiogenic growth factors. RNA was
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tissue culture ﬂasks (n = 3/group). Total RNA was isolated using the
RNeasy minikit (Qiagen). cDNA was prepared using RT2 First Strand
Kit (Qiagen). Using an iCycler iQ (BioRad), baseline and threshold
were set according to manufacturer's instruction (Qiagen). Only arrays
that passed the PCR Array Reproducibility, RT Efﬁciency and Genomic
DNA contamination tests were included in the analysis. Data
was analyzed using the RT2 Proﬁler PCR Array Data Analysis v3.5
(SABiosciences). Average Delta(Ct) was calculated by the fol-
lowing equation: (Ct(gene of interest) − Avg Ct(housekeeping
genes)). Fold-change (2(−Delta Delta Ct)) is the normalized gene expres-
sion (2(−Delta Ct)) in the test sample (oSVF) divided the normalized
gene expression (2(−Delta Ct)) in the control (ySVF). Fold regulation is
equal to fold change. To analyze how well grouped the oSVF gene fold
changes relative to ySVF were, standard error bars were calculated
using the multi-plot functionality of the RT2 Proﬁler PCR Array Data
Analysis v3.5 (SABiosciences). Fold change for speciﬁed genes was plot-
ted and a conﬁdence interval or error bar was generated using the fol-
lowing equation: σFC = FC ∗ ln2 ∗ sqrt(σx2 / nx + σy2 / ny) where FC
correlates to the fold change, σ represents the standard deviation, n re-
ﬂects the sample size, and x and y are the oSVF and ySVF sample values,
respectively. p values were generated using Student's t-test statistical
analysis with p b 0.05 being considered signiﬁcant.
2.6. Flow cytometry
Cell surfacemarkerswere characterized in the SVF cell population by
ﬂow cytometry using a LSR II ﬂow cytometer (BD Biosciences). The SVF
cells were freshly isolated, ﬁltered through a 100 μm screen to remove
large debris, and cell markers for VEGFR2, c-Kit (Abcam), CD11b
(eBioscience), CD31 (BD Biosciences), CXCR2 (R&D Systems), CD47,
CD34, and PDGFR (Santa Cruz) were used. Secondary antibodies,
when appropriate, were used (goat-anti-rabbit and Streptavidin,
Abcam). Antibody dilutions were optimized for each marker. Single
color tubes were used to generate compensation controls. Tubes con-
taining unstained SVF and additional tubes treated with appropriate
isotype controls were used in setting discrimination gates. Positive pop-
ulations were identiﬁed by quadrant gating dot plots using FlowJo 7.6.2
analysis software (Tree Star Inc, Ashland, OR).
2.7. Protein isolation and western blot
Total protein extract of ySVF, oSVF, and two- and four-week con-
struct explants with ySVF or oSVF was quantiﬁed using a Bradford Pro-
tein Assay (Bio-Rad). Protein isolated from rat spleen tissue served as a
positive control for Thbs-1 (Kaur et al., 2013). Protein samples were
combined with non-reducing sample buffer (62.5 mM Tris–HCl, 25%
Glycerol, 1% Bromophenol Blue; used as 10×) and ran on 4–20% Mini-
Protean® TGX™ Gels (BioRad 456-1094) at 100 V under non-reducing
conditions (running buffer: 25 mM Tris, 192 mM Glycine). Electropho-
resis was followed by transfer to a PVDF membrane (Millipore
IPFL00010) at 40 V at 4 °C. Blots were blocked with 5% dry milk for
1 h at RT, probed with non-reduced anti-thrombospondin-1 (α-Thbs-
1) antibody (1:500, 2 μg/mL, Tsp Ab-3(C6.7), Thermo Scientiﬁc) over-
night at 4 °C and anti-beta-actin (1:1000, Santa Cruz) for loading con-
trol. Fluorescently tagged goat-anti-mouse IgG Dylight 488 antibody
(2 μg/mL, Vector Labs) for 2 h at RT was used to detect bound primary
antibodies. Densitometry was performed using ImageJ software (NIH).
Results were normalized to loading control ﬁrst, and then to ySVF
Thbs-1 levels for reporting.
2.8. TUNEL staining
Constructs were explanted, processed through parafﬁn and 5 μm
sections obtained and mounted on slides. Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) was performed using theDeadEnd Fluorometric TUNEL system (Promega G3250) with the addi-
tion of counterstaining with 4′,6-diamidino-2-phenylindole (DAPI).
Three images of each stained construct were obtained with an
epiﬂuorescent microscope (Olympus IX51). Images were overlaid
(TUNEL+ and DAPI+) and double positive cells and total cells were
counted using cellSens Standard (Olympus America Inc, Central Valley,
PA).
2.9. Vasculogenic assessment and thrombospondin-blocking effect on
in vivo construct development
To evaluate the role of thrombospondin-1 in neovascularization, we
performed antibody blocking experiments in oSVF constructs and
explanted after two weeks. oSVF constructs were processed as in
Section 2.2 with the addition of an α-Thbs-1 antibody according to
manufacturer's recommended concentration (0.06 M, Tsp Ab-3(C6.7),
Thermo Scientiﬁc) or a control anti-mouse IgG1 antibody (Santa Cruz)
prior to polymerization. The conditions tested were oSVF plus control
IgG (oSVF + IgG) and oSVF plus α-Thbs-1 antibody (oSVF + α-Thbs-
1). Constructs were analyzed and results reported the same as the
four-week constructs described in Section 2.2.
2.10. Statistical analysis
Data is expressed as mean values ± SE except for ﬂow cytometry
data presented asmean values± SD. Comparison of two homoscedastic
groups was done with unpaired two-tailed Student's t-test. Statistical
signiﬁcance was set at p b 0.05. Each N corresponds to separate SVF iso-
lations from separate rats.
3. Results
3.1. Age of SVF donor determines extent of functional vascular network
assembly
To determine whether the age of donor SVF cells effects neovascu-
larization, in vivo collagen constructs containing either ySVF or oSVF
were implanted subcutaneously into mice and explanted after four
weeks. Vessel formation was examined by counting perfused and total
vessels (Fig. 1A). At four weeks, a decrease in the mean total vessels in
oSVF constructs (35.5± 3.0 vessels/mm2) compared to ySVF constructs
(55.4 ± 7.4 vessels/mm2) was observed (Fig. 1B). A decrease in the
mean count of perfused vessels for oSVF constructs (16.9 ± 2.0 ves-
sels/mm2, N = 11) compared to the mean count for ySVF constructs
(29.9± 6.1 vessels/mm2, N=13)was also observed (Fig. 1C). Network
functionwas analyzed by volume-calculatedVVIF percentagewhere the
volume of perfused vessels was divided by the volume of total vessels.
ySVF construct vessels showed a higher percent of perfused volume
than oSVF (ySVF = 46.9 ± 8.17%, N = 11; oSVF = 26.1 ± 2.82%, N =
12; Fig. 1D). Network architecture and vascular maturation were
assessed by vessel diameter frequency distribution at four weeks in
ySVF and oSVF (Fig. 1E). These distributions show that ySVF constructs
contain larger, more mature vessels compared to constructs with oSVF.
3.2. SVF characterization prior to implant
To identify possible reasons for the differences in vascular network
formation observed in the in vivo constructs, we considered that cell vi-
abilitywithin the oSVFwas reduced upon initial implant. However, LIVE/
DEAD assay revealed similar viability between ySVF and oSVF cell iso-
lates (ySVF= 81.6 ± 3.9%, N= 9, oSVF= 87.8 ± 4.9%, N= 15; Fig. 2A).
Another possible reason may be that expression of angiogenesis-
related genes in SVF isolates from young and old donors may differ. An-
giogenic growth factor gene array was performed on SVF isolated from
each age group (n = 3 arrays/group, each donor SVF = 1 array). Sur-
prisingly, SVF from old rats exhibited an increase in expression of
Fig. 1. Reduced neovascularization potential of SVF from old donors. Collagen constructs containing freshly isolated SVF from young or old donors (young n = 13, old n = 11) were im-
planted in Rag1mice for four weeks. Prior to explant, perfused vessels were stained with dextran–rhodamine and post-explant all vessels were stained with GS-1-ﬂuorescein. Constructs
were imaged by confocal microscopy (A). SVF constructs from old donors showed a reduction in total and perfused vessel density (B, C). A reduction in the percent of perfused vessel
volume (volume perfused vessels / volume total vessels × 100)was observed in networks formed by old SVF (D). Analysis of the size distribution of vessels showed a shift towards smaller
diameters in old SVF constructs at four weeks (young n = 7, old n = 8) (E). Scale bars are 100 μm, *p b 0.05.
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HGF (2.8-fold), and PDGFβ (4.04-fold) (Table 1), but none of these
reached statistical signiﬁcance. Of note, oSVF exhibited increased foldFig. 2.Donor age effects expression of angiogenesis-related factors in SVF. LIVE/DEAD assay (yo
(A). Flow cytometry of freshly isolated SVF (n=3 per group) revealed age-dependent expressio
or PDGFR (B).Western blot analysis showed increased expression of the anti-angiogenic matric
quantiﬁcation are shown (E). *p b 0.05.expression of thrombospondin-1 (Thbs-1, 6.72-fold), a matricellular
protein associatedwith potent inhibition of angiogenesis andmigration
(Table 1). All genes analyzed are listed in Supplementary Table 1.ung n= 9, old n= 15) showed no age related difference in viability of freshly isolated SVF
n of the cell surface receptors VEGFR2, CD47, and CXCR2, but not CD11b, CD31, CD34, cKit,
ellular protein thrombospondin-1 in old SVF (n= 7 both groups). Representative blot and
Table 1
Selected genes from angiogenesis gene array (84 genes total) comparing primary isolation of ySVF to oSVF. Angiopoeitin-2 (Angpt2), chemokine (CXCmotif) ligand 5 (CXCL5), granulin,
hepatocyte growth factor (Hgf), platelet-derived growth factor beta polypeptide (PDGFβ), Thbs-1, tyrosine kinasewith immunoglobin-like and EGF-like domains 1 (Tie1), tumor necrosis
factor (Tnf) and VEGFA were all upregulated in oSVF compared to ySVF. Angiopoeitin-like 4 (Angptl4) and transforming growth factor beta 1 (Tgfβ1) were both negatively expressed in
oSVF compared to ySVF. Fold regulation is the up–down regulation in old SVF compared to young SVF. Fold-regulation values greater than 2 are indicated in red, less than−2 are indicated
in blue.
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for select cell surface markers associated with angiogenesis, stem cell
differentiation, and inﬂammation markers. SVF cell isolates from
young and old animals (n ≥ 3 per group) were stained for VEGFR2,
PDGFR (angiogenesis), and CD47 (angiogenesis, receptor for Thbs-1),
c-Kit and CD34 (stem cell), CD11b (inﬂammation), CD31 (endothelial
cell marker), and CXCR2 (inﬂammation, receptor for CXCL5). The SVF
cell isolates exhibited an age-related difference in the number of cells
positive for VEGFR2+ (ySVF = 18.7 ± 3.4%, oSVF = 10.0 ± 1.1%) and
CXCR2+ (ySVF = 0.6 ± 0.2%, oSVF = 2.2 ± 0.6%). In addition, a bright
sub-population of CD47+ cells was reduced in old compared to young
(ySVF = 82.6 ± 1.9%, oSVF = 69.3 ± 2.8%; Fig. 2B). However, this
change was relatively small. Representative dot plots for markers
exhibiting signiﬁcant age-related differences are shown in Supplemen-
tal Fig. 2. No other investigated cell markers exhibited age related differ-
ences (Fig. 2B).
Since Thbs-1 is such a potent inhibitor of angiogenesis and has been
shown to limit recovery of ischemic tissue (Isenberg et al., 2007), and
because of the corresponding age-related differences in Thbs-1 gene ex-
pression and CD47 cell marker expression, we decided to further ex-
plore Thbs-1 in the present study. Fig. 2C shows an age-dependent
increase in Thbs-1 protein expression for oSVF compared to ySVF. The
oSVF had nearly double Thbs-1 expression at 191 ± 28.9% when nor-
malized to the ySVF values (100 ± 8.2%, N = 7 per group; Fig. 2C).
This data shows a clear age-dependent change in the expression of
Thbs-1 in SVF at the onset of construct formation and may be responsi-
ble for the decrease in neovascularization seen in the oSVF implants.
Thbs-1 was undetectable in both ySVF and oSVF two- and four-week
explanted constructs (data not shown).
3.3. Time-dependent rate of apoptosis in implanted vascular networks
Age-related decrease in SVF-dependent neovascularizationmight be
attributed to post-vasculogenic alterations, such as increased pruning
during the remodeling or maturation phase of network formation.
Therefore, we analyzed cell density and apoptosis in constructs
explanted at two-weeks and four-weeks. Cell apoptosis does not differbetween ySVF (N= 2) and oSVF (N = 5) at two weeks, but ySVF apo-
ptosis signiﬁcantly drops from 2.1 ± 0.3% at two weeks to 0.6 ± 0.2%
at four weeks (N = 10) while oSVF apoptosis remains stable from
1.5 ± 0.6% to 1.7 ± 0.5% (N = 10; Fig. 3A). Cell density is similar be-
tween ySVF (2541 cells/mm2, N = 2) and oSVF (2589 cells/mm2,
N = 5) at two weeks, but a signiﬁcant drop of 57.4% in cell density oc-
curs with the oSVF at four weeks (1198 cells/mm2) while ySVF at four
weeks maintains its cell density (ySVF = 2735 cells/mm2, N = 10 per
group; Fig. 3B). This data shows that apoptosis and subsequent network
pruning/remodeling decreases in ySVF implants between two and four
weeks, but oSVF implants maintain high apoptotic rates which could
contribute to the signiﬁcant vascular pruning/remodeling observed by
four weeks.
3.4. Antibody blocking effect of thrombospondin-1 on neovascularization
To determine whether the neovascularization deﬁcit developed by
oSVF relates to an increased contribution fromThbs-1-related inhibition
of angiogenesis, we evaluated vascular network characteristics of oSVF
constructs treated with Thbs-1 or control IgG antibody after two
weeks in vivo. Total vessels and total perfused vessels were similar be-
tween groups (N ≥ 3; Fig. 4B, C). However, antibody blockade of
Thbs-1 improved the percent of perfused vascular volume in oSVF com-
pared to oSVF + IgG (Fig. 4D). Interestingly, vessel diameter distribu-
tions of oSVF with Thbs-1 antibody at two weeks resemble ySVF
diameter distributions at four weeks (Fig. 1E), suggesting that by
blocking Thbs-1 the vascular network from oSVF is able to develop a
more mature vascular network.
4. Discussion
Adipose-derived stromal vascular fraction cells exhibit the ability to
form tube-like structures in vivo and support the accelerated formation
of newmicrovascular structures when implanted in collagen gels. Stud-
ies were performed to explore how advanced agemodiﬁes the ability of
adipose SVF to accelerate neovessel formation. The adipose SVF
suspended in a collagen construct progresses through distinct phases
Fig. 3. Time-dependent in vivo apoptosis in SVF constructs. TUNEL staining of SVF constructs revealed a decrease in apoptosis of young SVF from two to fourweekswhile levels of apoptosis
remained elevated in old SVF (twoweeks young n= 2, old n=5; fourweeks n= 10 both groups) (A). A corresponding reduction in cell density was noted in old SVF at fourweeks (two
weeks young n = 2, old n= 5; four weeks n= 10 per group) (B). *p b 0.05 notes differences between age groups, #p b 0.05 notes differences between time points within an age group.
23A.L. Aird et al. / Experimental Gerontology 63 (2015) 18–26of neovascularization until explant four weeks later, most notably
vasculogenesis/sprouting angiogenesis, inosculation, neovascular re-
modeling, and followed by vascular maturation (LeBlanc et al., 2012;
Nunes et al., 2010, 2013). The major ﬁndings support the conclusion
that the aging process contributes to remarkably less complete vascular
networks formed in vivo (Fig. 1) and a novel and somewhat surprising
mechanism was uncovered. SVF from old rats exhibited comparableFig. 4.Perfused volume of vessels formedby old SVF is improvedby thrombospondin-1 antibody
suspended in collagen constructs, and implanted in Rag1 mice for two weeks. Perfused vessels
(old+ IgG ab n=4, old+α-Thbs-1 n= 3). Representative images are shown (A). No differen
Thbs-1 signiﬁcantly increased the percent of vessel volume that was perfused (vol. perfused ves
towards a larger diameter in α-Thbs-1 treated SVF constructs (E). Scale bars are 100 μm, *p b 0expression of an endothelial marker (CD31+) and yield of endothelial
tubes formed in vitro when compared to ySVF (Fig. 2B and Supplemen-
talmaterial). But follow-up experiments revealed that signiﬁcant vascu-
lar regression (~50% less vessels, Fig. 1B, C) likely due to a sustained rate
of apoptosis between two and fourweeks in the oSVF implants (Fig. 3A).
This suggests that vasculogenic cells from old donors are not remiss in
the ability to form vessels at the onset, but rather, the new vesselsincubation.Old SVFwas treatedwith control IgG or thrombospondin-1 blocking antibody,
were labeled with dextran–rhodamine and all vessels were labeled with GS-1-ﬂuorescein
ceswere seen between groups in total or perfused vessel density (B, C). Treatmentwithα-
sels / vol. total vessels × 100) (D). Analysis of the size distribution of vessels showed a shift
.05.
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By acutely blocking Thbs-1, a potent anti-angiogenic protein, we were
able to increase the volume of perfused vessels formed and develop
larger more mature vessels from oSVF. Importantly, the number of ves-
sels formed was similar to constructs without Thbs-1 neutralizing anti-
body, which further supports the dysfunction with post-angiogenesis
activities in oSVF. We believe that this is a novel and important ﬁnding
because it implicates that therapies designed to grow new blood vessels
in ischemic tissue should include a focus on improving the inosculation,
remodeling and maturation phases of neovascularization in patients of
advanced age (LeBlanc et al., 2012).
Thbs-1, which can signal through cell surface receptor CD47, is
a matricellular glycoprotein that plays a signiﬁcant role in anti-
angiogenic processes through direct inﬂuence of endothelial cell migra-
tion and survival, and by indirect effects on mobilizing growth factors
(Lawler, 2002). Thbs-1 and CD47-null mice aged 14–18 months have
previously shown superior ischemic tissue survival and improved vas-
cular perfusion compared to age-matched controls hours after hindlimb
ischemia, but this wasn't evaluated long-term (Isenberg et al., 2007).
Endothelial cells isolated from CD47-null mice have been shown to
exhibit enhanced proliferation and decreased cellular senescence
(Kaur et al., 2013). Western blot analysis in the current study showed
1.91-fold higher expression of Thbs-1 protein in oSVF as compared to
ySVF (Fig. 2C), but ﬂow cytometry showed a decrease in the number
of cells brightly expressing CD47 in oSVF as compared to ySVF
(69.3+/− 2.8% v 82.6+/− 1.9%, p b 0.05, Fig. 2B). Since Thbs-1 signals
through the cell surface receptor CD47, it would appear that these
changes might counteract one another and prevent increased signaling
through the Thbs-1/CD47 axis. However, it should be noted that while
Thbs-1 protein levels are nearly doubled in oSVF, the corresponding de-
crease in number of CD47++ cells is more modest (0.16-fold decrease).
It is not likely that the decrease in CD47++ cells is large enough to bal-
ance the substantial increase in Thbs-1 expression that was observed.
Another important consideration is that Thbs-1 has many known li-
gands besides CD47. Binding of the CD36 receptor on endothelial cells
by Thbs-1 has been shown to inhibit neovascularization in vitro and
in vivo (Dawson et al., 1997; Jimenez et al., 2000). A possible role of
Thbs-1/CD36 signaling in the reduced neovascular potential of oSVF is
an area for future study.
A recent study found that age-associated capillary rarefaction in
mice could be abrogated by disrupting Thbs-1, which in turn attenuated
the upregulation of angiopoietin-2 (Ang-2) (Gonzalez-Quesada et al.,
2013), anothermediator of vascular regression.We show in the present
study that Thbs-1 and Ang-2 are both upregulated in oSVF compared to
ySVF (Table 1, Fig. 2C). Since oSVF retains the ability to assemble and
form vascular networks comparable in number to ySVF, but undergoes
signiﬁcant rarefaction once these vessels become patent, it is likely
that Thbs-1 signaling is involved. Antibody blocking of Thbs-1 improved
the volume of perfused vessels created in oSVF constructs and promot-
ed the growth and persistence of larger diameter vessels at two weeks.
This suggests that a chronic blockade of Thbs-1may be able to interrupt
the later stages of neovascularization between two and four weeks,
when vascular remodeling/rarefaction and maturation primarily domi-
nate neovascularization activities. These results identify a potential
mechanism by which suppressing Thbs-1 may retard the potent rare-
faction and anti-angiogenic effects observed in old SVF and lead to vas-
cular maturation and improved neovascularization.
Another plausiblemechanismbywhich aging and Thbs-1may play a
role in SVF vascular network formation is at earlier time points in the
neovascularization process, notably vessel sprouting/formation and in-
osculation. Almost 20 years ago, Thbs-1 was shown to inhibit the tran-
sition from a resting to a sprouting phenotype in endothelial cells
(Canﬁeld and Schor, 1995), giving credence to an “angiogenic switch”
that can be turned on or off in certain systems. Subsequently, Thbs-1
was found to induce apoptosis of endothelial cells in vitro and in vivo
(Jimenez et al., 2000). Theoretically, an age-dependent increase inThbs-1 protein in oSVF constructs at the time of implantation may be
causing early apoptosis of new vessels, hindering eventual network for-
mation. However, this is unlikely due to the fact that oSVF constructs
treated with Thbs-1 neutralizing antibody demonstrate similar number
of vessels formed after two weeks when compared to control antibody
constructs (Fig. 4), and this is conﬁrmed by our in vitro results (Supple-
mentary data). This suggests that there is no Thbs-1-related decrement
in the angiogenesis phase of in vivo neovascularization of SVF from
aged animals. Further, Thbs-1 protein was undetectable in two- and
four-week constructs made from oSVF (data not shown). This supports
the strong possibility that there might be age-dependent differences
in the inosculation phase, independent of Thbs-1 contribution, but more
experiments are needed to explore this time point of neovascularization.
The microarray analysis shown in Table 1 reveals up-regulation of
several genes in oSVF that may inﬂuence its neovascular and inﬂamma-
tory activity. The ELR+ CXC motif chemokine CXCL5 (30.9-fold in-
crease) is a potent neutrophil chemoattractant and has been shown to
play a role in tumor angiogenesis (White et al., 2003). Aptly, our ﬂow
cytometry results show increased presence of cells expressing the
ELR+ chemokine receptor CXCR2, which could possibly indicate an in-
creased neutrophil presence in oSVF. Granulin (17.3-fold increase)
mediates both pro-inﬂammatory and anti-inﬂammatory responses de-
pending on cleavage state and the local environment (Jian et al.,
2013). The uncleaved protein, known as progranulin, has been shown
to inhibit inﬂammatory signaling through the TNF pathway, but cleav-
age by neutrophil-derived elastase forms the pro-inﬂammatory mole-
cule granulin (Jian et al., 2013). It is possible that CXCL5 drives the
cleavage of progranulin to granulin by increasing neutrophil presence,
pushing the cytokine network balance towards a pro-inﬂammatory
state. Further evidence of increased inﬂammatory status in oSVF
is revealed by the increased expression of TNF (3.4-fold increase). TNF
is known to activate caspases that result in apoptosis as well as
the pro-inﬂammatory transcription factors AP-1 and NF-κB (Baud
and Karin, 2001), the latter of which has been shown to mediate age-
related endothelial dysfunction (Donato et al., 2009). Increased expres-
sion of these inﬂammatory markers in oSVF may be a consequence
of age-related low-grade systemic or vascular inﬂammation in the
donor animals (Franceschi et al., 2007). Since the therapeutic potential
of SVF and other MSC populations in ischemic disease, transplantation,
and other applications is mediated in large part by immunomodulation
and promotion of tissue integrity, an age-related change in the inﬂam-
matory status of SVF is of primary concern to translational studies.
It is commonly believed that aging results in a tissue environment
that is not conducive to promoting the growth of new vessels andmain-
taining them past the initial angiogenic phase. For example, stimulating
angiogenesis in an old mouse through implanting collagen constructs
embedded with growth factor results in decreased capillary ingrowth
compared to those implanted in young mice (Swift et al., 1999).
Coparabiotic studies have suggested that circulating factors contribute
to the poor recovery from injury and angiogenic dysfunction observed
in aged animals (Conboy et al., 2013; Pietramaggiori et al., 2009) and
heterochronic parabiotic pairings have shown an improvement in the
function of resident progenitor cells of the aged animal (Conboy and
Rando, 2012). Therefore, the presence of one or more “young” circulat-
ing factors may be critical to improve angiogenesis and injury repair in
the aged environment. However, a recent study contradicts this theory.
De Barros et al. (2013) showed that implanting human ADSCs from do-
nors (aged over 50 years) into a youngmousemodel of hindlimb ische-
mia did not improve cutaneous bloodﬂow compared to younger donors
(20–35 years) (De Barros et al., 2013). This suggests that a young envi-
ronment may not be able to fully overcome innate age-related changes
in angiogenic function in cells from old donors, despite potential bene-
ﬁcial circulating factors from young hosts. The present study supports
this, as SVF from old donors was unable to achieve neovascularization
to a level similar to young SVF even though it was implanted in a
young host (Fig. 1).
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SVF in an old host would result in even more inferior vascular growth
than demonstrated in the present study due to “old”, potentially delete-
rious circulating factors. This is because the cohort most commonly
afﬂicted with ischemia, and needing subsequent vascular therapies, is
the aged population. Host/recipient age-related comparisons have
been completed utilizing BMSCs in a mouse model of hindlimb ische-
mia. By varying donor cell age/recipient host age, Zhuo et al. (2010) re-
ported young/young as achieving the highest arteriolar and capillary
density, followed by similar results between young/old and old/young,
and ﬁnallymarking old/old as the fewest vessels formed following inju-
ry and cell treatment (Zhuo et al., 2010). Therefore, not only do the iso-
lated cells from old donors retain age-related neovascularization
dysfunction, but also the extent of vascular regeneration potentially
could be even less if implanted in the aged population. This is especially
important to discern in future studies because of the clinical relevance
of autologous cell-based therapies.
The current paradigm is that regenerative cells act primarily through
paracrine mechanisms (e.g. production of angiogenic factors) to induce
neovascularization, tissue repair, and evoke responses from resident
cells (Baraniak and McDevitt, 2010; Duran et al., 2013; Gnecchi et al.,
2008; Hatzistergos et al., 2010). When implanted in conjunction with
a growth factor (FGF2) into an ischemic tissue environment, ADSCs pro-
duce even more growth factors (VEGF, HGF, FGF2) and result in im-
proved survival and blood perfusion in young donors and hosts
(Bhang et al., 2009). In 2011, Koh et al. implanted SVF in matrigel sup-
plemented with both VEGF-A and angiopoietin-1 (Ang1) and reported
9.7-fold increase in vascular perfusion after two weeks compared to
SVF alone (Koh et al., 2011), but did not evaluate if this effect persisted
during later stages of neovascularization. Although the present study
did not supplement with growth factors in vivo, our study did show
that conditioned media collected from young SVF did not improve an-
giogenic characteristics of oSVF in vitro (Supplemental material). It's
possible that the addition of 2–3 growth factors could improve angio-
genesis in vivo, but it's more likely that the acute incubation of the
oSVF constructs with embedded growth factors would only improve
initial vessel density (0–2 weeks) and would not persist long enough
to participate in the vascular remodeling and maturation phases.
SVF is a relatively easy cell source to obtain but is frequently sub-
selected and extensively cultured to obtain expanded, speciﬁc cell
populations (i.e. ADSCs, CD34+/CD133+, c-kit+, etc.). Cultured SVF
from old mice demonstrated lower VEGF production, proliferation and
tubulogenesis compared to SVF from young mice (El-Ftesi et al.,
2009). Recently, a subpopulation (CD45−/CD34+/CD133+) isolated
from the adipose tissue of elderly humans showed decreased angiogen-
ic potential of progenitor cells, as measured by in vitro tube/network
formation, compared to young, healthy counterparts (Madonna et al.,
2011). Other studies have gone on to demonstrate that adipose-
derived cells from older patients exhibit shorter telomeres, reduced tel-
omerase activity (Madonna et al., 2013) and less angiogenic factor pro-
duction (De Barros et al., 2013; Eﬁmenko et al., 2014). The present study
is unique in that it utilizes the entire SVF population from an established
agingmodel and employed no culturing, passaging, and sub-selection to
evaluate in vivo neovascularization potential; all in an effort to more
closely resemble future autologous clinical applications where SVF can
be isolated and implanted almost simultaneously. Further, this study is
the ﬁrst to examine the relationship between Thbs-1, adipose-derived
SVF and neovascularization in advancing age. The results of this study
emphasize the need to further examine post-angiogenesis phases of
neovascularization for the development of future ischemic therapies,
but some limitations of the present study should be considered.
4.1. Limitations of the study, future studies
In this study we observed an age-related reduction in the neo-
vascular potential of adipose SVF. These studies are based on a singledose of cells and future studies will need to establish the dose depen-
dency of adipose SVF cell therapies to support new blood vessel forma-
tion. To better understand the vascular remodeling events responsible
for this decline, explant of vascular constructs at additional time points
(at inosculation and between two and four weeks) or the use of a skin
fold window model for real time visualization would be needed. The
mechanisms underlying the reduction in neovascular potential with
age are not fully established, however, our results strongly support
that aging-induced changes in Thbs-1 expression may contribute. The
complex nature of the interaction between chemokines, inﬂammation,
and angiogenesis requires many subsequent studies to identify the
mechanisms by which increases in CXCL5/CXCR2 or Thbs-1/CD36 sig-
naling may possibly inﬂuence neovascularization. The aging process
may also change the relative distribution of different cell types in the
heterogeneous SVF cell population as well as the ability of cells to syn-
thesize and excrete paracrine factors. This study used an in vivo model
of neovascularization using a collagen construct implanted in healthy
Rag1 mice. The site of implantation, the disease state of the recipient
and the age of the recipient may also have an effect on the neovascular-
ization process.5. Conclusion
This study evaluated the effects of aging on the ability of adipose de-
rived stromal vascular fraction cells to support accelerated neovascular-
ization. There is an age-dependent impairment in the formation of
functional microvascular networks following implantation of adipose
SVF cell containing collagen constructs. Thrombospondin-1 plays a
role in the observed reduction in neovascularization using adipose SVF
fromold animals. These results have direct implications for future autol-
ogous therapies designed for treating ischemic disease in the elderly.
Supplementary data to this article can be found online at http://dx.
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